{"id":33496,"date":"2025-05-15T14:35:06","date_gmt":"2025-05-15T06:35:06","guid":{"rendered":"https:\/\/flcube.com\/?p=33496"},"modified":"2025-05-15T14:35:07","modified_gmt":"2025-05-15T06:35:07","slug":"jiangsu-hengrui-pharmaceuticals-launches-hong-kong-ipo-of-h-shares","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=33496","title":{"rendered":"Jiangsu Hengrui Pharmaceuticals Launches Hong Kong IPO of H-Shares"},"content":{"rendered":"\n

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276<\/a>) has officially launched an initial public offering (IPO) on the Hong Kong Stock Exchange. The company is issuing 224,519,800 H-shares, with 212,171,200 shares allocated to the global offering. The shares are priced at a maximum of HKD 44.05 (USD 5.64) each, aiming to raise HKD 9.89 billion (USD 1.3 billion).<\/p>\n\n\n\n

Global Offering Details<\/strong>
Under the global offering, Jiangsu Hengrui Pharmaceuticals will grant over-allotment options to international underwriters. These options allow underwriters to require the company to issue up to 33,677,800 additional H-shares (assuming no exercise of the offer size adjustment clause) or up to 38,729,600 additional H-shares at the offering price. The options may be exercised by the lead underwriter from the date of the international underwriting agreement until June 19, 2025, within 30 days after the closing of the Hong Kong public offering.-Fineline Info & Tech<\/a><\/p>\n\n\n\n